User profiles for Houssein H. Ayoub
 | Houssein Ayoub, Ph.DAssistant Professor of Applied Mathematics, Qatar University Verified email at qu.edu.qa Cited by 7668 |
[HTML][HTML] Protection against the Omicron variant from previous SARS-CoV-2 infection
Protection against Omicron by Previous SARS-CoV-2 Infection Using a national Covid-19
database in Qatar, investigators found that previous SARS-CoV-2 infection provided protection …
database in Qatar, investigators found that previous SARS-CoV-2 infection provided protection …
[HTML][HTML] Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
…, HA Al Khatib, P Coyle, HH Ayoub… - … England Journal of …, 2021 - Mass Medical Soc
Background Waning of vaccine protection against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The …
coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The …
[HTML][HTML] Effects of previous infection and vaccination on symptomatic omicron infections
Background The protection conferred by natural immunity, vaccination, and both against
symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the …
symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the …
[HTML][HTML] Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar
…, H Chemaitelly, HH Ayoub… - … England Journal of …, 2022 - Mass Medical Soc
Background Waning of vaccine protection against coronavirus disease 2019 (Covid-19)
and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory …
and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory …
[HTML][HTML] mRNA-1273 COVID-19 vaccine effectiveness against the B. 1.1. 7 and B. 1.351 variants and severe COVID-19 disease in Qatar
The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna)
vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-…
vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-…
[HTML][HTML] Protective effect of previous SARS-CoV-2 infection against Omicron BA. 4 and BA. 5 subvariants
… Anvar H. Kaleeckal, M.Sc. … Mohamed H. Al-Thani, MD … Ayoub HH, Tomy M,
Chemaitelly H, et al. Estimating protection afforded by prior infection in preventing …
Chemaitelly H, et al. Estimating protection afforded by prior infection in preventing …
[HTML][HTML] Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants in Qatar
SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted
a matched, test-negative, case-control study to estimate duration of protection of the second …
a matched, test-negative, case-control study to estimate duration of protection of the second …
[HTML][HTML] BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant,
we conducted a matched test-negative case–control study to assess the real-world …
we conducted a matched test-negative case–control study to assess the real-world …
[HTML][HTML] Immune imprinting and protection against repeat reinfection with SARS-CoV-2
Immune Responses to SARS-CoV-2 Reinfection Evidence from this cohort study suggests
that an earlier infection with pre-omicron SARS-CoV-2 before a first omicron infection may …
that an earlier infection with pre-omicron SARS-CoV-2 before a first omicron infection may …
[HTML][HTML] SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
…, YA Mohamoud, S Younuskunju, HH Ayoub… - …, 2021 - thelancet.com
Background Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has been documented, raising public health concerns. SARS-CoV-2 reinfections were …
has been documented, raising public health concerns. SARS-CoV-2 reinfections were …